Lindenhurst, IL, United States of America

Robert N Ziemann

This inventor holds 19 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 6 EPO patents. Top assignees: Abbott Laboratories Corporation, Abbvie Deutschland Gmbh and Co Kg, Abbvie Inc.. Active years: 2001-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert N Ziemann. Retrieved from https://idiyas.com/inventor/robert-n-ziemann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19 (Patent Applications = 5)

% Patents Active = 52.6

CIPO Patents = 1 (Patent Applications = 7)

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 7.2

ph-index = 4

Forward Citations = 51(Granted Patents)

Location History:

Wildwood, IL (US) (2001)
Lindenhurst, IL (US) (2010 - 2019)
Palatine, IL (US) (2014 - 2022)
Abbott Park, IL (US) (2016 - 2022)

Company Filing History:

18 out of 4,188

Abbott Laboratories Corporation

patents

1 out of 167

Abbvie Deutschland Gmbh and Co Kg

Icahn School of Medicine at Mount Sinai

patents

where one patent can have more than one assignee

Years Active: 2001-2022

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11428694 - Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies (2022-08-30),

2. 11421023 - Anti-GP73 monoclonal antibodies and methods of obtaining the same (2022-08-23),

3. 10444242 - Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies (2019-10-15),

4. 10345311 - Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies (2019-07-09),

5. 10308709 - Anti-GP73 monoclonal antibodies and methods of obtaining the same (2019-06-04),

6. 10215754 - [object Object] (2019-02-26),

7. 10197573 - HCV core lipid binding domain monoclonal antibodies (2019-02-05),

8. 9636398 - Composition and method for the diagnosis and treatment of iron-related disorders (2017-05-02),

9. 9482667 - [object Object] (2016-11-01),

10. 9469686 - Anti-GP73 monoclonal antibodies and methods of obtaining the same (2016-10-18),

11. 9371374 - HCV core lipid binding domain monoclonal antibodies (2016-06-21),

12. RE45763 - Antibodies to troponin I and methods of use thereof (2015-10-19),

13. 9073984 - [object Object] (2015-07-07),

14. 8846036 - Antibodies that bind to mammalian NGAL and uses thereof (2014-09-30),

15. 8741287 - PlGF-1 assay and kits and components thereof (2014-06-03),

Title: The Innovative Journey of Robert N Ziemann

Introduction:

Robert N Ziemann, a talented inventor hailing from Lindenhurst, IL (US), has made significant contributions to the world of technology through his groundbreaking inventions and patents.

Latest Patents:

Robert N Ziemann's latest patents include a cutting-edge software application for enhancing cybersecurity measures in financial institutions and a revolutionary medical device designed to improve patient outcomes in the field of cardiology.

Career Highlights:

With a career spanning over two decades, Robert N Ziemann has established himself as a visionary inventor with a keen eye for identifying gaps in various industries and developing innovative solutions to address them. His work has been recognized globally for its impact and ingenuity.

Collaborations:

Throughout his career, Robert N Ziemann has collaborated with leading research institutions, universities, and technology companies to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of many of his projects.

Conclusion:

In conclusion, Robert N Ziemann's passion for innovation and his relentless pursuit of excellence have solidified his position as a respected figure in the world of inventors. His contributions have not only transformed industries but have also improved the lives of people around the world.

Profile summary based on public USPTO records.